Therapeutic blockade of the programmed cell death protein 1 (PD-1) and the cytotoxic T-lymphocyte associated protein 4 (CTLA-4) immune checkpoints has emerged as a powerful strategy for cancer treatment in multiple cancer types by reinvigorating exhausted T cells 1,2. This evidence concerns the gene CTLA4 and cancer.